Emerging Infectious Disease ISSN: 1080-6059

Genome Sequence and Attenuating Mutations in West Nile Virus Isolate from Mexico

David W.C. Beasley*

, C. Todd Davis*, Jose Estrada-Franco*, Roberto Navarro-Lopez†, Arturo Campomanes-Cortes†, Robert B. Tesh*, Scott C. Weaver*, and Alan D.T. Barrett*

Author affiliations: *University of Texas Medical Branch, Galveston, Texas, USA; †Comision Mexico-Estados Unidos para la Prevencion de la Fiebre Aftosa y Otras Enfermedades Exoticas de los Animales, Mexico City, Mexico

Main Article

Figure 1

Western blot showing differing mobility of E proteins from nine plaque-purified variants of West Nile virus (WNV) strain TM-171 Mex03. Nucleotide sequencing of strains in lanes 5 to 9 indicated the presence of an “NYS” glycosylation motif at residues 154 to 156 of E, while strains in lanes 1 to 4 encoded “NYP.” Antigens were separated in a nonreducing 5%/10% discontinuous sodium dodecyl sulfate–polyacrylamide gel, transferred to 0.2 μm nitrocellulose and detected with WNV-specific monoclonal ant

Figure 1. Western blot showing differing mobility of E proteins from nine plaque-purified variants of West Nile virus (WNV) strain TM-171 Mex03. Nucleotide sequencing of strains in lanes 5 to 9 indicated the presence of an “NYS” glycosylation motif at residues 154 to 156 of E, while strains in lanes 1 to 4 encoded “NYP.” Antigens were separated in a nonreducing 5%/10% discontinuous sodium dodecyl sulfate–polyacrylamide gel, transferred to 0.2 μm nitrocellulose and detected with WNV-specific monoclonal antibody 7H2 (6).

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.